TY - JOUR
T1 - Tocotrienol-rich fraction and levodopa regulate proteins Involved in Parkinson’s disease-associated pathways in differentiated neuroblastoma cells
T2 - Insights from quantitative proteomic analysis
AU - Magalingam, Kasthuri Bai
AU - Ramdas, Premdass
AU - Somanath, Sushela Devi
AU - Selvaduray, Kanga Rani
AU - Bhuvanendran, Saatheeyavaane
AU - Radhakrishnan, Ammu Kutty
N1 - Funding Information:
This study was funded by the Jeffrey Cheah School of Medicine and Health Sciences Internal grant scheme.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Tocotrienol-rich fraction (TRF), a palm oil-derived vitamin E fraction, is reported to possess potent neuroprotective effects. However, the modulation of proteomes in differentiated human neuroblastoma SH-SY5Y cells (diff-neural cells) by TRF has not yet been reported. This study aims to investigate the proteomic changes implicated by TRF in human neural cells using a label-free liquid-chromatography-double mass spectrometry (LC-MS/MS) approach. Levodopa, a drug used in the treatment of Parkinson’s disease (PD), was used as a drug control. The human SH-SY5Y neuroblastoma cells were differentiated for six days and treated with TRF or levodopa for 24 h prior to quantitative proteomic analysis. A total of 81 and 57 proteins were differentially expressed in diff-neural cells following treatment with TRF or levodopa, respectively. Among these proteins, 32 similar proteins were detected in both TRF and levodopa-treated neural cells, with 30 of these proteins showing similar expression pattern. The pathway enrichment analysis revealed that most of the proteins regulated by TRF and levodopa are key players in the ubiquitin-proteasome, calcium signalling, protein processing in the endoplasmic reticulum, mitochondrial pathway and axonal transport system. In conclusion, TRF is an essential functional food that affects differential protein expression in human neuronal cells at the cellular and molecular levels.
AB - Tocotrienol-rich fraction (TRF), a palm oil-derived vitamin E fraction, is reported to possess potent neuroprotective effects. However, the modulation of proteomes in differentiated human neuroblastoma SH-SY5Y cells (diff-neural cells) by TRF has not yet been reported. This study aims to investigate the proteomic changes implicated by TRF in human neural cells using a label-free liquid-chromatography-double mass spectrometry (LC-MS/MS) approach. Levodopa, a drug used in the treatment of Parkinson’s disease (PD), was used as a drug control. The human SH-SY5Y neuroblastoma cells were differentiated for six days and treated with TRF or levodopa for 24 h prior to quantitative proteomic analysis. A total of 81 and 57 proteins were differentially expressed in diff-neural cells following treatment with TRF or levodopa, respectively. Among these proteins, 32 similar proteins were detected in both TRF and levodopa-treated neural cells, with 30 of these proteins showing similar expression pattern. The pathway enrichment analysis revealed that most of the proteins regulated by TRF and levodopa are key players in the ubiquitin-proteasome, calcium signalling, protein processing in the endoplasmic reticulum, mitochondrial pathway and axonal transport system. In conclusion, TRF is an essential functional food that affects differential protein expression in human neuronal cells at the cellular and molecular levels.
KW - Parkinson’s disease
KW - proteomics
KW - SH-SY5Y neuroblastoma cells
KW - tocotrienol-rich fraction (TRF)
UR - http://www.scopus.com/inward/record.url?scp=85141571698&partnerID=8YFLogxK
U2 - 10.3390/nu14214632
DO - 10.3390/nu14214632
M3 - Article
C2 - 36364894
AN - SCOPUS:85141571698
SN - 2072-6643
VL - 14
JO - Nutrients
JF - Nutrients
IS - 21
M1 - 4632
ER -